5-氯-2-苯基-3H-咪唑-4-甲醛 | 60367-52-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氯-2-苯基-3H-咪唑-4-甲醛
• 中文别名: 5-氯-2-苯基-1H-咪唑-4-甲醛
• 英文名称: 5-chloro-2-phenyl-1H-imidazole-4-carboxaldehyde
• 英文别名: 5-Chloro-2-phenyl-1H-imidazole-4-carbaldehyde
• CAS: 60367-52-4
• 化学式: C₁₀H₇ClN₂O
• mdl: MFCD01935953
• 分子量: 206.631
• InChiKey: CCXUATWKEDQRMP-UHFFFAOYSA-N

物化性质

• 熔点：
  172-174°
• 沸点：
  440.8±25.0 °C(Predicted)
• 密度：
  1.378±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Chloro-2-phenyl-3H-imidazole-4-carbaldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Chloro-2-phenyl-3H-imidazole-4-carbaldehyde
CAS number: 60367-52-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H7ClN2O
Molecular weight: 206.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-2-苯基-3H-咪唑-4-甲醛 在 氢氧化钾 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 1,3-二溴-5,5-二甲基海因 、 偶氮二异丁腈 作用下， 以 乙二醇二甲醚 、 环己烷 、 异丙醇 为溶剂， 反应 6.0h， 生成 3-[4-(4-chloro-5-formyl-2-phenyl-imidazol-1-ylmethyl)phenyl]-5-isobutylthiophene-2-(3-ethyl) sulfonylurea
  参考文献：
  名称：

  ¹⁴C-Labeled and Large-Scale Synthesis of the Angiotensin-(1−7)-receptor Agonist AVE 0991 by Cross-Coupling Reactions

  摘要：

  The synthesis of C-14-labeled AVE 0991 (C-14-1a) and large-scale synthesis of AVE 0991 (1a) are described. In the key step of the synthesis, the C-C coupling reaction of the imidazole (2) and thiophene (3) building blocks was studied under Suzuki and Stille reaction conditions, respectively. Suzuki reaction gave only moderate yields, whereas the best results were obtained under Stille reaction conditions with up to 64% yield.

  DOI：

  10.1021/jo034372c
• 作为产物：
  描述：

  2-([亚氨基](苯基)甲基]氨基)乙酸 在 sodium hydroxide 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 5-氯-2-苯基-3H-咪唑-4-甲醛
  参考文献：
  名称：

  Process for the production of 2-substituted

  摘要：

  一种制备2-取代的5-氯咪唑-4-甲醛的方法，其一般公式为：##STR1## 在该方法中，甘氨酸与一般公式为：##STR2## 的亚胺酯发生反应，产生的中间体通过威尔斯迈尔试剂转化为产物。这些2-取代的5-氯咪唑-4-甲醛是制备药物或除草活性化合物的有价值的中间体。

  公开号：

  US05696272A1

文献信息

• SUBSTITUTED SULFONAMIDE COMPOUNDS
  申请人：OBERBOERSCH Stefan

  公开号：US20080153843A1

  公开（公告）日：2008-06-26

  Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

  磺胺取代物，其制备方法，含有这些化合物的药物组合物，以及磺胺取代物在治疗或抑制疼痛和/或各种疾病或疾病状态中的用途。
• PYRIDINE DERIVATIVE
  申请人：TEIJIN PHARMA LIMITED

  公开号：US20150284358A1

  公开（公告）日：2015-10-08

  Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.

  提供的是由化学式（I）表示的吡啶衍生物，其前药，吡啶衍生物或前药的药用可接受盐，或者吡啶衍生物，前药或药用可接受盐的溶剂，用于治疗或预防与URAT1相关的疾病，如痛风，高尿酸血症，高血压，肾脏疾病如间质性肾炎，糖尿病，动脉硬化和Lesch-Nyhan综合征。
• Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
  申请人：sanofi-aventis

  公开号：EP1939180A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环丙烯酰胺， 其中Het、X、Ra、Rb、R1、R2和R3具有权利要求中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I化合物的方法，包括它们的药物组合物，以及利用式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile
  作者：Hidekazu Tokuhara、Yasuhiro Imaeda、Yoshiyuki Fukase、Koichi Iwanaga、Naohiro Taya、Koji Watanabe、Ray Kanagawa、Keisuke Matsuda、Yumiko Kajimoto、Keiji Kusumoto、Mitsuyo Kondo、Gyorgy Snell、Craig A. Behnke、Takanobu Kuroita

  DOI：10.1016/j.bmc.2018.04.051

  日期：2018.7

  S3 pocket. In the course of modification, renin inhibitory activity was enhanced by the formation of an additional hydrogen bonding with the hydroxyl group of Thr77. Consequently, a series of novel benzimidazole derivatives were discovered as potent and orally bioavailable renin inhibitors. Among those, compound 13 exhibited more than five-fold of plasma renin inhibition than aliskiren in cynomolgus

  我们先前确定了2-叔丁基-4-[（3-甲氧基丙基）氨基] -N-（2-甲基丙基）-N-[（3S，5R）-5-（吗啉-4-基羰基）哌啶-3- yl] pyrimidine-5-carboxamide 3作为有效的肾素抑制剂。由于3在大鼠中显示出不可接受的低生物利用度（BA），因此使用SBDD并着重于理化性质进行结构修饰，以改善其PK谱，同时保持肾素抑制活性。在嘧啶的4-位上连接的氨基转化为亚甲基可改善PK谱并降低肾素抑制活性。探索了具有碳侧链的新中心核，以提高效能。我们设计了一系列与亲脂性S3口袋相互作用的5元唑和稠合杂环。在修改过程中，通过与Thr77的羟基形成额外的氢键，肾素抑制活性得到增强。因此，发现了一系列新型的苯并咪唑衍生物作为有效的和口服可生物利用的肾素抑制剂。在这些化合物中，按剂量比，化合物13在食蟹猴中表现出的血浆肾素抑制能力比阿利吉仑高出五倍。
• Substituted sulphonyl cyanamides, method for producing same and their use as medicament
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06573288B1

  公开（公告）日：2003-06-03

  The invention relates to compounds of formula (I) in which the symbols have the meanings given in the claims. Said compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of myocardial infarction, angina pectoris, diseases caused by ischaemia, impaired respiration, cardiac ischaemia, ischaemia of the peripheral and central nervous system and stroke, ischaemia of the peripheral organs and limbs and diseases in which cell proliferation is a primary or secondary cause, in the treatment of shock, during surgical interventions and organ transplants or for preserving and storing transplants to be used in surgical interventions.

  该发明涉及式(I)的化合物，其中符号具有索赔中给出的含义。所述化合物是钠依赖性碳酸氢盐/氯离子交换体的抑制剂，可用作预防或治疗多种疾病的药物，例如治疗和/或预防心肌梗死、心绞痛、缺血引起的疾病、呼吸受损、心脏缺血、周围和中枢神经系统的缺血和中风、周围器官和肢体的缺血以及细胞增殖是主要或次要原因的疾病，在休克治疗中，在外科手术和器官移植期间或用于保存和储存用于外科手术的移植物。